Rani Therapeutics/RANI

$7.07

11.07%
-
1D1W1MYTD1YMAX

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Ticker

RANI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mir Imran

Employees

140

Headquarters

San jose, United States

RANI Metrics

BasicAdvanced
$393.73M
Market cap
-
P/E ratio
-$1.33
EPS
-
Beta
-
Dividend rate
$393.73M
$8.75
$1.82
115.3K
6.365
190.3
228.362
-37.05%
-81.81%
-136.64%
-131.29%
28.769
30.603
-4.04%

What the Analysts think about RANI

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
25.32% upside
High $12.00
Low $4.00
$7.07
Current price
$8.86
Average price target

RANI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-7M
-23.08%
Profit margin
0%
-

RANI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.35%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.33
-$0.37
-$0.36
-$0.27
-
Expected
-$0.41
-$0.40
-$0.37
-$0.31
-$0.20
Surprise
-20.19%
-8.48%
-1.55%
-13.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Rani Therapeutics stock?

Rani Therapeutics (RANI) has a market cap of $303.45M as of April 20, 2024.

What is the P/E ratio for Rani Therapeutics stock?

The price to earnings (P/E) ratio for Rani Therapeutics (RANI) stock is 0 as of April 20, 2024.

Does Rani Therapeutics stock pay dividends?

No, Rani Therapeutics (RANI) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Rani Therapeutics dividend payment date?

Rani Therapeutics (RANI) stock does not pay dividends to its shareholders.

What is the beta indicator for Rani Therapeutics?

Rani Therapeutics (RANI) does not currently have a Beta indicator.

What is the Rani Therapeutics stock price target?

The target price for Rani Therapeutics (RANI) stock is $8.86, which is 25.32% above the current price of $7.07. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rani Therapeutics stock

Buy or sell Rani Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing